• IgAN is the most common type of glomerulonephritis worldwide, affecting an estimated 120,000 patients in the US1
  • Deposits of IgA complexes in the glomerular mesangium trigger an immune response that results in persistent inflammation, proteinuria, glomerular fibrosis, and ultimately a reduction of kidney function progressing to ESRD1,2

PHOENIX Trial Overview

PHOENIX was an open-label, multicenter, phase 2 US trial designed to evaluate the safety, tolerability, and efficacy of bardoxolone methyl in four separate patient cohorts. The target enrollment is 25 to 30 patients per cohort.

PHOENIX Trial Details

  • Patient cohorts: ADPKD, IgAN, T1D CKD, and FSGS
    • Age: 18-65 years
    • eGFR: 30-90 mL/min/1.73 m2
  • Primary endpoint: change from baseline in eGFR at week 12
  • Treatment: bardoxolone methyl, orally, once daily for 12 weeks

PHOENIX Trial Design


  1. Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: Current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-148.
  2. National Institute of Diabetes and Digestive and Kidney Diseases. IgA nephropathy. www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy. Accessed November 8, 2018.
View References